Explore the words cloud of the ORBIS project. It provides you a very rough idea of what is the project "ORBIS" about.
The following table provides information about the project.
UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU
|Coordinator Country||Poland [PL]|
|Total cost||2˙268˙000 €|
|EC max contribution||2˙268˙000 € (100%)|
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
|Duration (year-month-day)||from 2018-03-01 to 2022-02-28|
Take a look of project's partnership.
|1||UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU||PL (POZNAN)||coordinator||684˙000.00|
|2||POLITECHNIKA POZNANSKA||PL (POZNAN)||participant||369˙000.00|
|3||JOINT STOCK COMPANY FARMAK||UA (KIJEV)||participant||315˙000.00|
|4||SIEC BADAWCZA LUKASIEWICZ - INSTYTUT FARMACEUTYCZNY||PL (WARSZAWA)||participant||274˙500.00|
|5||ZENTIVA, K.S.||CZ (Prague)||participant||270˙000.00|
|6||HELSINGIN YLIOPISTO||FI (HELSINGIN YLIOPISTO)||participant||171˙000.00|
|7||THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN||IE (DUBLIN)||participant||112˙500.00|
|8||PHYSIOLUTION GMBH||DE (GREIFSWALD)||participant||45˙000.00|
|9||APPLIED PROCESS COMPANY LIMITED||IE (DUBLIN)||participant||27˙000.00|
|10||RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY||US (NEW BRUNSWICK)||partner||0.00|
The current process of drug development is lengthy and inefficient. Only 1 out of approximately 10,000 drug molecules enters the market. Therefore more effective medicines, demanded by society, cannot be provided by pharmaceutical industry. To fill this gap, Open Research Biopharmaceutical Internships Support (ORBIS) proposes that the high attrition rate of new drug candidates might be reduced by over 20% by improving early stage R&D productivity. The overarching objective of ORBIS is therefore to form an international and inter-sectoral academic and industrial network. The action is aimed at improving the preclinical pathway of medicine development concentrating on processes and technologies. The goal is to integrate multidisciplinary research by involving academia and industry from EU (Poland, Ireland, Finland, Germany and Czech Republic), EU associated country (Ukraine) and US to address the poor drug bioavailability as 70% of actives have solubility and/or membrane permeability problems. The action is addressed at selected molecules of class II and IV of Biopharmaceutics Classification System, to improve their pharmaceutical potential. The complementary consortium comprises experts in computations, physical chemistry, material science, nanotechnology, pharmacy, pharmacology and bioanalysis. The secondments will create a stimulating environment for early stage researchers to advance their individual career and soft skills. EU scientists will amalgamate their expertise in drug synthesis and dissolution, oral formulations, and bioanalytical methods with the knowledge on dermal research provided by the US partner. ORBIS will consolidate the existing links, promote long-term cooperation and exchange of knowledge between beneficiaries and partners. ORBIS will also enhance dissemination of new research outcomes and raise the awareness among the general public of the importance of drug delivery research that makes new drugs more accessible and affordable for society.
|Mid-term meeting.||Other||2020-01-14 15:07:29|
|Workshop on dosage forms and drug delivery systems.||Other||2019-10-15 13:13:56|
|2nd School on oral dosage and drug delivery systems.||Other||2019-10-15 13:14:08|
|1st School on pharmaceutical preformulation testing of APIs and dosage forms.||Other||2019-10-15 12:11:42|
|Open Workshop on process development of drug substances.||Other||2019-10-15 12:11:42|
|Kick-off meeting.||Other||2019-10-15 12:11:42|
|ORBIS website launched + Social media channels established.||Websites, patent fillings, videos etc.||2019-10-15 12:11:42|
Take a look to the deliverables list in detail: detailed list of ORBIS deliverables.
|year||authors and title||journal||last update|
Piotr J. Rudzki, PrzemysÅ‚aw Biecek, MichaÅ‚ Kaza
Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?
published pages: , ISSN: 1550-7416, DOI: 10.1208/s12248-019-0293-2
|The AAPS Journal 21/2||2019-10-15|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORBIS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ORBIS" are provided by the European Opendata Portal: CORDIS opendata.